Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.

Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.

Spartà AM, Bressanin D, Chiarini F, Lonetti A, Cappellini A, Evangelisti C, Evangelisti C, Melchionda F, Pession A, Bertaina A, Locatelli F, McCubrey JA, Martelli AM.

Cell Cycle. 2014;13(14):2237-47. doi: 10.4161/cc.29267. Epub 2014 May 29.

2.

Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe.

Li J, Hong MJ, Chow JP, Man WY, Mak JP, Ma HT, Poon RY.

Oncotarget. 2015 Apr 20;6(11):9327-40.

3.

Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.

Shin SB, Woo SU, Yim H.

J Cell Physiol. 2015 Dec;230(12):3057-67. doi: 10.1002/jcp.25042.

PMID:
25975351
4.

Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.

Cani A, Simioni C, Martelli AM, Zauli G, Tabellini G, Ultimo S, McCubrey JA, Capitani S, Neri LM.

Oncotarget. 2015 Mar 30;6(9):6597-610.

5.

Targeting sonic hedgehog-associated medulloblastoma through inhibition of Aurora and Polo-like kinases.

Markant SL, Esparza LA, Sun J, Barton KL, McCoig LM, Grant GA, Crawford JR, Levy ML, Northcott PA, Shih D, Remke M, Taylor MD, Wechsler-Reya RJ.

Cancer Res. 2013 Oct 15;73(20):6310-22. doi: 10.1158/0008-5472.CAN-12-4258. Epub 2013 Sep 25.

6.

Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma.

Stehle A, Hugle M, Fulda S.

Cancer Lett. 2015 Aug 28;365(1):37-46. doi: 10.1016/j.canlet.2015.04.011. Epub 2015 Apr 23.

PMID:
25917079
7.

Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells.

Yuan CX, Zhou ZW, Yang YX, He ZX, Zhang X, Wang D, Yang T, Wang NJ, Zhao RJ, Zhou SF.

Drug Des Devel Ther. 2015 Jan 14;9:487-508. doi: 10.2147/DDDT.S74127. eCollection 2015.

8.

Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells.

Ding YH, Zhou ZW, Ha CF, Zhang XY, Pan ST, He ZX, Edelman JL, Wang D, Yang YX, Zhang X, Duan W, Yang T, Qiu JX, Zhou SF.

Drug Des Devel Ther. 2015 Jan 9;9:425-64. doi: 10.2147/DDDT.S74062. eCollection 2015.

9.

Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition.

Kreis NN, Louwen F, Zimmer B, Yuan J.

Oncotarget. 2015 Mar 30;6(9):6611-26.

10.

Aurora kinases as targets in drug-resistant neuroblastoma cells.

Michaelis M, Selt F, Rothweiler F, Löschmann N, Nüsse B, Dirks WG, Zehner R, Cinatl J Jr.

PLoS One. 2014 Sep 30;9(9):e108758. doi: 10.1371/journal.pone.0108758. eCollection 2014.

11.

Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.

Chiarini F, Falà F, Tazzari PL, Ricci F, Astolfi A, Pession A, Pagliaro P, McCubrey JA, Martelli AM.

Cancer Res. 2009 Apr 15;69(8):3520-8. doi: 10.1158/0008-5472.CAN-08-4884. Epub 2009 Apr 7.

12.

Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia.

Pereira JK, Machado-Neto JA, Lopes MR, Morini BC, Traina F, Costa FF, Saad ST, Favaro P.

Eur J Cancer. 2015 Sep;51(14):2076-85. doi: 10.1016/j.ejca.2015.07.018. Epub 2015 Jul 31.

PMID:
26238016
13.

Modeling the mitotic regulatory network identifies highly efficient anti-cancer drug combinations.

Wu Y, Zhuo X, Dai Z, Guo X, Wang Y, Zhang C, Lai L.

Mol Biosyst. 2015 Feb;11(2):497-505. doi: 10.1039/c4mb00610k.

PMID:
25418836
14.

A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.

Lin YW, Beharry ZM, Hill EG, Song JH, Wang W, Xia Z, Zhang Z, Aplan PD, Aster JC, Smith CD, Kraft AS.

Blood. 2010 Jan 28;115(4):824-33. doi: 10.1182/blood-2009-07-233445. Epub 2009 Nov 23.

15.

Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia.

Simioni C, Neri LM, Tabellini G, Ricci F, Bressanin D, Chiarini F, Evangelisti C, Cani A, Tazzari PL, Melchionda F, Pagliaro P, Pession A, McCubrey JA, Capitani S, Martelli AM.

Leukemia. 2012 Nov;26(11):2336-42. doi: 10.1038/leu.2012.136. Epub 2012 May 22.

PMID:
22614243
16.

MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel.

Shimomura T, Hasako S, Nakatsuru Y, Mita T, Ichikawa K, Kodera T, Sakai T, Nambu T, Miyamoto M, Takahashi I, Miki S, Kawanishi N, Ohkubo M, Kotani H, Iwasawa Y.

Mol Cancer Ther. 2010 Jan;9(1):157-66. doi: 10.1158/1535-7163.MCT-09-0609. Epub 2010 Jan 6.

17.

Survival of primary, but not of cancer cells after combined Plk1-HDAC inhibition.

Lange L, Hemmerich P, Spänkuch B.

Oncotarget. 2015 Sep 22;6(28):25801-14. doi: 10.18632/oncotarget.4445.

19.

The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation.

Li L, Wang X, Chen J, Ding H, Zhang Y, Hu TC, Hu LH, Jiang HL, Shen X.

Acta Pharmacol Sin. 2009 Oct;30(10):1443-53. doi: 10.1038/aps.2009.141.

20.

Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells.

Hartsink-Segers SA, Exalto C, Allen M, Williamson D, Clifford SC, Horstmann M, Caron HN, Pieters R, Den Boer ML.

Haematologica. 2013 Oct;98(10):1539-46. doi: 10.3324/haematol.2013.084434. Epub 2013 Jun 10.

Items per page

Supplemental Content

Write to the Help Desk